MHDNA probe and its application in hypochlorous acid imaging of ulcerative colitis

By designing MHDNA probes, using the oxidation of HClO to trigger catalytic hairpin assembly, efficient and convenient detection of ulcerative colitis and visual imaging of inflammatory areas of ulcerative colitis, solving the diagnostic sensitivity and cost in the prior art High-quality problems have achieved efficient and inexpensive detection of ulcerative colitis.

CN118207209BActive Publication Date: 2024-11-15XI AN JIAOTONG UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410388008.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-01
Publication Date
2024-11-15
Estimated Expiration
2044-04-01

AI Technical Summary

Technical Problem

The existing diagnostic methods for ulcerative colitis are insufficient in sensitivity and specificity, and are expensive, and lack efficient, convenient and inexpensive detection methods.

Method used

A MHDNA probe was designed to form a tetravalent cross-shaped DNA structure through base complementary pairing assembly, combining fluorescent reporter groups and fluorescence quenching groups, and using the oxidation of HClO to trigger catalytic hairpin assembly to achieve amplification of fluorescent signal. and detection.

Benefits of technology

High sensitivity detection of hypochlorous acid HClO and visual imaging of inflammatory areas of ulcerative colitis were achieved, which significantly improved diagnostic efficiency and accuracy, and had good biocompatibility and economicality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118207209B_ABST
    Figure CN118207209B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of hypochlorous acid (HClO) detection, and specifically relates to an MHDNA probe and its application in hypochlorous acid imaging of ulcerative colitis. The MHDNA probe is composed of Hpa with a sequence as shown in SEQ ID NO.5 and Hpb with a sequence as shown in SEQ ID NO.6, which are assembled on a tetravalent cross-shaped DNA structure composed of M1, M2, M3 and M4 shown in SEQ ID NO.1 to 4 through base complementary pairing; the base T at the 22nd position of M3 is modified with thiophosphate; and the Hpa is modified with a fluorescent reporter group and a fluorescent quencher group. The MHDNA probe of the present invention is combined with a catalytic hairpin assembly (CHA) reaction to sensitively and specifically detect HClO, so as to achieve in vivo imaging and disease diagnosis of inflammatory bowel disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of hypochlorous acid (HClO) detection, and particularly relates to an MHDNA probe and an application thereof in hypochlorous acid imaging of ulcerative colitis. Background Art

[0002] Ulcerative colitis (UC) is a chronic inflammatory disease that affects the gastrointestinal tract, with an increasingly high recurrence rate, which seriously affects the quality of life of patients. Currently, non-invasive detection methods such as positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) have been used for the diagnosis of UC. However, the lack of diagnostic sensitivity and specificity, as well as the high cost, still limit them. Therefore, it is urgent to construct an efficient, convenient, and inexpensive diagnostic method for UC.

[0003] As an inflammatory disease, it has been reported that immune cells infiltrate and accumulate in the colon of UC patients, especially neutrophils and monocytes. Both neutrophils and monocytes uniquely secrete heme-containing myeloperoxidase (MPO). Under the catalysis of MPO, hydrogen peroxide overexpressed in the inflammatory site reacts with chloride (Cl - ) undergoes a peroxidation reaction to generate hypochlorous acid (HClO). Therefore, direct detection of HClO is helpful for early detection and diagnosis of early IBD.

[0004] At present, there are various methods for detecting HClO, including colorimetry, electrochemistry, fluorescence, chromatography, etc. Among them, fluorescence has become a hot spot for HClO detection due to its relatively accurate spatiotemporal resolution, non-invasive detection, high sensitivity and outstanding selectivity. Moreover, when combined with precision instruments such as microscopes and in vivo imaging systems, it can be used as a powerful tool for monitoring and analyzing disease-related biomolecules in living systems.

[0005] Deoxyribonucleic acid (DNA) is the main carrier of genetic information in biological systems and is vital to organisms. By precisely controlling the DNA sequence and specific base pairing rules, DNA has been used as a universal building block that can be assembled into specific editable nanostructures. As a natural nanoscale material, it has the advantages of good biocompatibility, reliable biodegradability, convenient synthesis and easy modification, which has attracted widespread interest among researchers. So far, a series of biomarker sensing methods based on DNA nanostructures have been established, including nucleic acids, antigens, antibodies and small molecules.

[0006] As a class of non-enzymatic nucleic acid amplification methods, catalytic hairpin assembly (CHA) has been demonstrated to be a versatile signal amplification and transduction tool. In traditional CHA, a nucleic acid initiator triggers the isothermal hybridization of two DNA hairpins, accompanied by the circulation of the nucleic acid initiator. However, traditional CHA relies on the random collision of two dissociated hairpins in solution, resulting in slow reaction kinetics and affecting the efficiency of detection. Summary of the invention

[0007] In order to solve the above technical problems, the present invention provides a MHDNA probe and its application in hypochlorous acid imaging of ulcerative colitis.

[0008] In a first aspect of the present invention, there is provided an MHDNA probe, wherein the MHDNA probe is composed of Hpa with a sequence as shown in SEQ ID NO.5 and Hpb with a sequence as shown in SEQ ID NO.6, assembled on a tetravalent cruciform DNA structure composed of M1, M2, M3 and M4 as shown in SEQ ID NOs.1 to 4 through complementary base pairing;

[0009] The base T at position 22 of M3 is modified with phosphorothioate;

[0010] The Hpa is modified with a fluorescent reporter group and a fluorescent quencher group.

[0011] Furthermore, the fluorescent reporter group is Cy5.5, and the fluorescent quencher group is BHQ3.

[0012] The second aspect of the present invention provides a method for preparing the MHDNA probe, comprising the following steps:

[0013] M1, M2, M3 and M4 were dissolved in a buffer solution, heated for 5 to 6 minutes, and naturally cooled to room temperature to form a tetravalent cross-shaped DNA structure;

[0014] The tetravalent cross-shaped DNA structure is incubated with Hpa and Hpb in a buffer at room temperature to obtain the MHDNA probe.

[0015] Furthermore, the heating temperature is 94-96°C.

[0016] Furthermore, the incubation time at room temperature is 1-1.5 h.

[0017] Furthermore, the buffer is Tris buffer.

[0018] The third aspect of the present invention provides the use of the MHDNA probe in detecting hypochlorous acid for non-diagnostic purposes.

[0019] In a specific embodiment of the present invention, the MHDNA probe is mixed with a solution containing HClO and reacted at room temperature. The MHDNA probe exhibits obvious fluorescence enhancement as the concentration of HClO increases, indicating that the detection of HClO by the MHDNA probe is feasible.

[0020] The fourth aspect of the present invention provides the use of the MHDNA probe in the preparation of a biosensor for auxiliary diagnosis and / or screening of ulcerative colitis.

[0021] In a specific embodiment of the present invention, the MHDNA probe was made into a solution (the solvent was water or a buffer, such as Tris buffer), and the solution was intravenously injected into the tail vein of healthy mice and ulcerative colitis (UC) model mice. After injection, fluorescence imaging was performed on the Xenogen IVIS system. The results showed that the fluorescence intensity of UC mice gradually increased over time, and the fluorescence intensity was significantly stronger than that of healthy mice, indicating that the MHDNA probe can visualize the upregulated HClO in the inflammatory area.

[0022] The fifth aspect of the present invention provides the use of the MHDNA probe in the preparation of a biosensor for auxiliary diagnosis and / or screening of ulcerative colitis, wherein the MHDNA probe is used for imaging hypochlorous acid at the inflammatory site of a patient with ulcerative colitis.

[0023] The sixth aspect of the present invention provides a biosensor for assisting diagnosis and / or screening of ulcerative colitis, wherein the active ingredient is the MHDNA probe.

[0024] The present invention has the following beneficial effects:

[0025] The present invention proposes for the first time a MHDNA probe for HClO sensing, which can trigger catalytic hairpin assembly (CHA) through a trigger (T) released by HClO, resulting in changes in the fluorescence signal. Figure 1 As shown, a mixture of M1, M2, M3 and M4 is annealed and hybridized to form a tetravalent cross, which has 6 single-stranded ends that can hybridize with hairpin a (Hpa) and hairpin b (Hpb) to form an MHDNA probe. In this DNA structure, Hpa, which is labeled with a fluorescent reporter group (Cy5.5) and a fluorescent quencher group (BHQ3) at the appropriate position, remains non-fluorescent due to the FRET effect. The M3 chain is modified with phosphorothioate (PS), which is particularly sensitive to the oxidation of HClO. In addition, PS modification does not affect base pairing and retains the programmability of DNA.

[0026] In the presence of HClO, the PS position in M3 breaks due to the hydrolysis of HClO, and T is released from the MHDNA probe. The released T hybridizes with Hpa, opening the Hpa hairpin structure. As a result, the modified Cy5.5 and BHQ3 on Hpa are moved away from each other, restoring the quenched fluorescence signal. The newly exposed Hpa sticky end hybridizes with Hpb, allowing T to be released again and enter the next CHA cycle, thereby achieving signal amplification. In the absence of HClO, the MHDNA probe remains intact, making CHA impossible, and no fluorescence signal can be observed. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Schematic diagram of the MHDNA probe for efficient and sensitive imaging of HClO.

[0028] Figure 2 A is the characterization of MHDNA probe. A is the PAGE characterization of MHDNA construction. B is the gel electrophoresis of MHDNA probe and free hairpin probe (Hpa, Hpb) incubated with 10% FBS for different time periods and the relative band intensity obtained by statistics.

[0029] Figure 3 The feasibility evaluation of MHDNA probe for detecting HClO. A is the PAGE characterization of the CHA process triggered by the T chain. B is the PAGE analysis after incubation of MHDNA probe with different concentrations of HClO. C is the fluorescence spectrum after incubation of MHDNA probe or control probe with HClO (1μM and 5μM). D is the real-time fluorescence monitoring of blank solution and 5μM HClO by MHDAN probe or FHDNA probe.

[0030] Figure 4 The performance of MHDNA probe is studied. A is the fluorescence spectrum of MHDNA probe in response to HClO with a concentration of 0 to 5 μM, and B is the fitting curve corresponding to A. C is the fluorescence spectrum of MHDNA probe in response to HClO with a concentration of 10 μM to 150 μM, and D is the fitting curve corresponding to B. E is the fluorescence spectrum of MHDNA probe in response to HClO and other analytes with a concentration of 5 μM. F is the (F-F0) / F0 change of MHDNA probe to HClO and other analytes. The data error bars represent mean ± SD (n = 3).

[0031] Figure 5Figure 2 is the fluorescence imaging of HClO by MHDNA probe in DSS-induced ulcerative colitis (UC) model. A is a schematic diagram of UC model establishment and in vivo HClO imaging. B is the concentration of lipocalin 2 (Lcn-2). C is the endoscopic images of mice in different groups. D is histological H&E staining. E is the in vivo HClO imaging of UC model mice at different times after injection of MHDNA probe, and F is the quantification of fluorescence intensity corresponding to E.

[0032] Figure 6 The in vivo biocompatibility evaluation of MHDNA probe. A is the blood routine index, B is the blood biochemical index, and C is the H&E staining of the main organs. DETAILED DESCRIPTION

[0033] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.

[0034] The materials and instruments involved in the following examples are:

[0035] All DNA oligonucleotides used in this paper were synthesized by Shanghai Sangon Biotechnology Co., Ltd., China, and the detailed sequences are shown in Table 1. Fetal bovine serum, hypochlorous acid (HClO), sodium phosphate dihydrate (Na2HPO4·12H2O), sodium dihydrogen phosphate dihydrate (NaH2PO4·2H2O), sodium chloride (NaCl), hydrogen peroxide (30%), magnesium chloride (MgCl2), and tris (hydroxymethylaminomethane) (Tris) were ordered from Aladdin Reagent Co., Ltd. (Beijing, China). 5× loading buffer (containing GelRed) was provided by Generay Biotech Co., Ltd. (Shanghai). Ultrapure water (≥18 MΩ) was obtained by a water purification system (HyperPureX, China).

[0036] Fluorescence spectra were measured using a fluorescence spectrometer (HITACHT-F4700, Japan). Native polyacrylamide gel electrophoresis (PAGE) was performed on a gel electrophoresis instrument from Biored, USA.

[0037] Table 1 Oligonucleotide sequence information

[0038]

[0039] T*: phosphorothioate (PS) modification, underline: Trigger (T). (1): Cy5.5 modification, (2) BHQ3 modification.

[0040] Example 1: Preparation and characterization of MHDNA probe

[0041] 1 Experimental methods

[0042] (1) Preparation of MHDNA probe

[0043] First, all single-stranded DNAs were dissolved in Tris buffer (20mM, pH7.9). Then, a mixture of equal amounts of single strands (M1, M2, M3, M4) was heated to 95°C for 5 minutes. After cooling to room temperature, a tetravalent cross DNA structure was formed. Then, the tetravalent cross was incubated with hairpins Hpa and Hpb in Tris buffer at room temperature for 1 hour. The resulting MHDNA probe was stored at 4°C for later use.

[0044] (2) Characterization of native polyacrylamide gel electrophoresis (PAGE)

[0045] The prepared DNA sample (8 μL, 1 μM) was mixed with 2 μL 5× loading buffer (containing GelRed). Then, the mixture was injected into a 12% gel. After running in 1× TBE buffer at 120 V for 60 minutes, the gel image was captured by a gel image analysis system (GIAS1500, China).

[0046] (3) Stability of MHDNA probe

[0047] MHDNA probes or dissociated hairpins (Hpa+Hpb) were incubated in 10% fetal bovine serum (FBS). After incubation for different time periods, the obtained products were characterized by gel electrophoresis, and the relative band intensity was quantified using Image j.

[0048] 2 Experimental results

[0049] like Figure 2 As shown in A, the complete M1, M2, M3 and M4 showed their own characteristic electrophoretic bands (lanes 1, 2, 3 and 4). The electrophoretic mobility of the mixture of M1, M2, M3 and M4 was slow (lane 5), indicating that the tetravalent cross structure was successfully assembled. The hairpin structure (Hpa or Hpb) showed a clear single-stranded band (lane 6 or lane 7). After Hpa, Hpb and the tetravalent cross DNA structure were mixed, their individual bands could not be observed, and a new band with a slower migration speed appeared (lane 8), indicating that Hpa and Hpb were successfully assembled on the tetravalent cross DNA structure through base complementary pairing to form the MHDNA probe.

[0050] like Figure 2 As shown in B, after incubation in 10% FBS for 3 hours, the DNA band intensity representing the MHDNA probe hardly changed, while the two dissociated hairpins were almost completely degraded, with the relative band intensity close to 0%, indicating that the stability of the MHDNA probe was significantly improved.

[0051] Example 2: Feasibility of MHDNA probe for detecting HClO

[0052] 1 Experimental methods

[0053] (1) Gel electrophoresis to assess feasibility

[0054] The prepared DNA sample (8 μL, 1 μM) was mixed with 2 μL of 5× loading buffer (containing GelRed). Then, the mixture was injected into a 12% gel. After running for 60 minutes at 120 V and 1× TBE buffer, the gel image was obtained by a gel image analysis system.

[0055] (2) Feasibility evaluation by fluorescence method

[0056] 5 μl of MHDNA probe or Control probe (M3 without PS modification) was incubated with 5 μl of HClO (1 μM or 5 μM) solution at room temperature, and then the fluorescence intensity was measured.

[0057] (3) Real-time monitoring of MHDNA probe fluorescence

[0058] 5 μl of MHDNA probe or FHDNA probe (containing a tetravalent cross structure and free Hpa and Hpb, i.e., the tetravalent cross structure has no free ends for binding Hpa and Hpb) was reacted with 5 μl of buffer or HClO (5 μM) solution at room temperature, and the fluorescence intensity at different reaction times was recorded.

[0059] 2 Experimental results

[0060] The feasibility of the HClO sensing method was first evaluated by gel electrophoresis, including the T-triggered CHA process and the cleavage of the MHDNA probe by HClO. Figure 3 As shown in A, Hpa, Hpb and T (lane 1, lane 2 and lane 3) present a single DNA band. When Hpa was incubated with T, a new electrophoretic band appeared (lane 4), indicating that T hybridized with Hpa to form a duplex complex. Lane 5 has two independent DNA bands, corresponding to Hpb and T, respectively, indicating that T cannot hybridize with Hpb. The solution containing Hpa and Hpb (lane 6) shows two bands at almost the same position, indicating that the hybridization between them fails in the absence of T. After T was incubated with Hpa and Hpb, a new band with a slower electrophoretic migration speed appeared (lane 7), indicating that CHA has occurred and formed an Hpa-Hpb complex. At the same time, T is released from it to participate in the next CHA process.

[0061] Then, the dissociation performance of HClO on M3 was studied. Figure 3As shown in B, after the MHDNA probe was incubated with HClO for a certain period of time, a new band with the same migration rate as T appeared, indicating that M3 in MHDNA was cleaved and T was released from the MHDNA probe.

[0062] A control probe without PS modification in M3 was designed. Then, the fluorescence spectra of the MHDNA probe and the Control probe were recorded as the target was added to confirm the feasibility of the HClO sensing method. When HClO was incubated with MHDNA and the control under the same conditions, the fluorescence of the control probe did not change compared with the blank. However, the MHDNA probe showed a significant fluorescence enhancement with the increase of HClO concentration ( Figure 3 C), indicating that the fluorescence recovery is caused by the hydrolysis reaction of PS and HClO, and this method is feasible for the detection of HClO.

[0063] Finally, in order to verify the reaction kinetics of the improved MHDNA probe, a tetravalent cross-shaped DNA structure FHDNA composed of dissociated Hpa and Hpb was constructed. Real-time fluorescence monitoring was performed by recording the changes in the fluorescence intensity of the FHDNA probe and the MHDNA probe in the presence or absence of HClO. In the absence of HClO, no fluorescence signal was observed for both the MHDNA and FHDNA probes ( Figure 3 D). After exposure to HClO, the fluorescence of MHDNA increased rapidly and reached a plateau at 90 min. Under the same conditions, the fluorescence signal of FHDNA increased slowly, which was slower than that of MHDNA, fully demonstrating the improvement of the reaction rate of MHDNA.

[0064] Example 3: In vitro analytical performance of MHDNA probe

[0065] 1 Experimental methods

[0066] 5 μL of MHDNA probe (5 μM) was mixed with 5 μL of HClO or non-target substances of different concentrations. After incubation at room temperature for 90 min, a certain amount of ddH2O was added, and the fluorescence intensity was recorded using a fluorescence spectrophotometer.

[0067] 2 Experimental results

[0068] For the HClO sensing platform, its analytical ability was evaluated by incubating with different concentrations of HClO. In the range of 0 to 150 μM, as the concentration of HClO increased, the fluorescence intensity gradually increased ( Figure 4 A and 4C). In the lower concentration range (0-5 μM), the relationship between the fluorescence intensity at 666 nm and the HClO concentration conforms to the regression equation F = 0.5876lgC HClO+1.914, the correlation coefficient is 0.9095( Figure 4 B). The detection limit (LOD) is 9.83 nM. At high concentrations of HClO (10 μM to 150 μM), the fitting curve is F = 3.3091 lgC HClO -8.162, the correlation coefficient is 0.9494( Figure 4 D).

[0069] In order to study the specificity of MHDNA probe, Na + , K + Mg 2+ , Ca 2+ 、F - 、HCO3 - 、NO2 - 、CO3 2- , Arg, Gly, His, H2O2, NO, TBHP, HClO and other substances were incubated with MHDNA probe. Compared with HClO, other non-target substances did not show obvious fluorescence signal recovery ( Figure 4 E and 4F), indicating that the MHDNA probe has good specificity for HClO.

[0070] Example 4: Fluorescence imaging of HClO in ulcerative colitis (UC) model

[0071] 1 Experimental methods

[0072] (1) Establishment and evaluation of UC model

[0073] Six-week-old C57BL / 6J female mice, weighing approximately 20 g, were purchased from the Medical Experimental Animal Center of Xi'an Jiaotong University, Shaanxi Province, China. All animal studies were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of Xi'an Jiaotong University. Healthy mice were randomly divided into two groups: 1) control group (n = 3), which were fed with normal water for 7 consecutive days. 2) DSS group (n = 3), which were fed with 2.5% (w / v) DSS for 7 consecutive days. To ensure the successful establishment of the UC model, we performed a series of experiments, including changes in colon length, intestinal H&E staining, endoscopic examination, and changes in the expression levels of inflammatory-related factors.

[0074] (2) Fluorescence imaging of HClO in vivo

[0075] Healthy mice and UC model mice were intravenously injected with 100 μl of 5 μM MHDNA probe via the tail vein. After injection, fluorescence imaging was performed on the Xenogen IVIS system. Fluorescence intensity was quantified by using the corresponding software. All imaging parameters were kept constant throughout the experiment.

[0076] 2 Experimental results

[0077] The establishment of ulcerative colitis mouse model and the process of imaging HClO are as follows Figure 5 A. To verify the successful establishment of UC, several tests were performed. First, the concentration of lipocalin 2 (Lcn-2) in mouse feces was measured using a commercial kit. The concentration of Lcn-2 in the DSS group was higher than that in the control group ( Figure 5 B). To observe the colon lesions directly, an endoscopic examination was performed. The colon was found to be uneven, with obvious ulcerative lesions and unclear blood vessels compared with the control group ( Figure 5 C). Colon H&E staining was performed to analyze colon structure and pathological changes. Crypt loss, inflammatory cell infiltration, goblet cell destruction, etc. were observed in the DSS group ( Figure 5 D). These results demonstrate the successful establishment of the UC model.

[0078] Then, all mice were intravenously injected with 100 μL of MHDNA probe. At different time points after probe injection, the mice were imaged with fluorescence on the IVIS imaging system. Figure 5 As shown in E and 5F, the fluorescence intensity of UC mice gradually increased over time. In addition, the fluorescence intensity of the DSS group was significantly stronger than that of the control group ( Figure 5 F), demonstrating that the MHDNA probe can visualize upregulated HClO in inflammatory regions.

[0079] Example 5: Evaluation of biocompatibility of MHDNA probe

[0080] 1 Experimental methods

[0081] Healthy C57BL / 6 mice were intravenously injected with 100 μl MHDNA probe or Tris buffer. The mice were killed 7 days after injection, and the main organs (heart, liver, spleen, lung, kidney) were taken for H&E staining. The collected blood was used for blood routine and blood biochemical analysis.

[0082] 2 Experimental results

[0083] There was no significant difference in blood routine indicators such as white blood cells, red blood cells, hemoglobin, lymphocytes, and platelets between the control group and the MHDNA group ( Figure 6 A). In addition, some blood biochemical indicators such as albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), urease (urea), and total protein (TP) showed no significant differences between the two groups ( Figure 6 B) H&E staining for histological evaluation of major organs. Figure 6 As shown in C, there were no obvious histological and physiological changes between the two groups. The results showed that the MHDNA probe had good in vivo biocompatibility.

[0084] It should be noted that when the claims of the present invention involve numerical ranges, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. In order to avoid redundancy, the present invention describes a preferred embodiment.

[0085] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0086] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. An application of MHDNA probe in detecting hypochlorous acid for non-diagnostic purposes, characterized in that: The MHDNA probe is composed of Hpa with a sequence as shown in SEQ ID NO.5 and Hpb with a sequence as shown in SEQ ID NO.6, which are assembled on a tetravalent cross-shaped DNA structure composed of M1, M2, M3 and M4 shown in SEQ ID NOs.1 to 4 through complementary base pairing; The base T at position 22 of M3 is modified with phosphorothioate; The Hpa is modified with a fluorescent reporter group and a fluorescent quencher group.

2. The use according to claim 1, characterized in that: The fluorescent reporter group is Cy5.5, and the fluorescent quencher group is BHQ3.

3. The use according to claim 1, characterized in that: The preparation method of the MHDNA probe comprises the following steps: Dissolve M1, M2, M3 and M4 in a buffer solution, heat for 5-6 minutes, and cool naturally to room temperature to form a tetravalent cross-shaped DNA structure; The tetravalent cross-shaped DNA structure is incubated with Hpa and Hpb in a buffer at room temperature to obtain the MHDNA probe.

4. The use according to claim 3, characterized in that: The heating temperature is 94~96℃.

5. The use according to claim 3, characterized in that: The incubation time at room temperature is 1-1.5h.

6. The use of the MHDNA probe according to claim 3, characterized in that: The buffer is Tris buffer.

7. Use of the MHDNA probe described in claim 1 in preparing a biosensor, characterized in that: The biosensor is used for auxiliary diagnosis and / or screening of ulcerative colitis. The biosensor realizes auxiliary diagnosis and / or screening of ulcerative colitis by imaging hypochlorous acid at the inflammatory site of the ulcerative colitis patient.

8. A biosensor, characterized in that: The active ingredient is the MHDNA probe described in claim 1, and the biosensor is used for auxiliary diagnosis and / or screening of ulcerative colitis.

Citation Information

Patent Citations

  • Electroluminescent sensor based on double-hairpin structure, and construction method and application of electroluminescent sensor

    CN110849867A

  • Construction method of proportional electrochemical sensor for detecting methylated DNA based on multi-layer DNA amplification loop

    CN113552191A

  • Isothermal nucleic acid amplification sensor for rapidly detecting hypochlorous acid and myeloperoxidase

    CN113736856A

  • Oligonucleotide probes and uses thereof

    WO2017161357A1